Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wim K Bleeker

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 1, 2004
Therapeutic antibody gene transfer: an active approach to passive immunityJoost M Bakker, Wim K Bleeker, Paul W H I Parren
European Journal of Nuclear Medicine and Molecular Imaging|November 11, 2010
Targeted multi-pinhole SPECTWoutjan Branderhorst, Brendan Vastenhouw, Frans van der Have, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2004
Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIbEdwin van Mirre, Jessica L Teeling, Jos W M van der Meer, et al.
Immunology|July 23, 2003
Rat C-reactive protein activates the autologous complement systemNiubel Diaz Padilla, Wim K Bleeker, Yvonne Lubbers, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Crosstalk between human IgG isotypes and murine effector cellsMarije B Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 27, 2010
Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosetsYolanda S Kap, Nikki van Driel, Erwin Blezer, et al.
Nature Medicine|June 16, 2009
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesAnn J Hessell, Pascal Poignard, Meredith Hunter, et al.
Cancer Research|August 4, 2006
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of actionJeroen J Lammerts van Bueren, Wim K Bleeker, Henrik O Bøgh, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2012
Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibilityJeroen J Lammerts van Bueren, Wim K Bleeker, Annika Brännström, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutationsMatthias Peipp, Tanja Schneider-Merck, Michael Dechant, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 1, 2004
Therapeutic antibody gene transfer: an active approach to passive immunityJoost M Bakker, Wim K Bleeker, Paul W H I Parren
European Journal of Nuclear Medicine and Molecular Imaging|November 11, 2010
Targeted multi-pinhole SPECTWoutjan Branderhorst, Brendan Vastenhouw, Frans van der Have, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2004
Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIbEdwin van Mirre, Jessica L Teeling, Jos W M van der Meer, et al.
Immunology|July 23, 2003
Rat C-reactive protein activates the autologous complement systemNiubel Diaz Padilla, Wim K Bleeker, Yvonne Lubbers, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Crosstalk between human IgG isotypes and murine effector cellsMarije B Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 27, 2010
Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosetsYolanda S Kap, Nikki van Driel, Erwin Blezer, et al.
Nature Medicine|June 16, 2009
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesAnn J Hessell, Pascal Poignard, Meredith Hunter, et al.
Cancer Research|August 4, 2006
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of actionJeroen J Lammerts van Bueren, Wim K Bleeker, Henrik O Bøgh, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2012
Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibilityJeroen J Lammerts van Bueren, Wim K Bleeker, Annika Brännström, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutationsMatthias Peipp, Tanja Schneider-Merck, Michael Dechant, et al.
Pageof 3